CAMBRIDGE, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent clinical developments, reaffirmed its commitment to advancing its Hsp90 chaperone inhibitor program, provided updated 2009 guidance, and announced first quarter 2009 financial results.
